A Phase 2A, Double Blind (3rd Party Open), 4 Way Cross-Over, Placebo Controlled Study To Investigate The Pharmacokinetics, Safety, Toleration And Efficacy Of Single Inhaled Doses Of PF-00610355 In Moderate COPD Patients.
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2012
At a glance
- Drugs PF 610355 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 28 Apr 2012 New source identified and integrated (EudraCT2008-001396-30: European Clinical Trials Database).
- 10 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 10 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.